Skip to content
TrialScanner

NCT04227106

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Phase 3CompletedABEOLead

Registry record

Lead sponsor
Abeona Therapeutics, Inc
Conditions
Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa
Primary completion
Oct 18, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04227106 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04227106: Phase 3, Open-label Clinical... | TrialScanner